If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

You’re more likely to find an empty bottle of Buckfast than used needles in Glasgow, even down city centre alleys concealed ...

Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, ...

David Lynch revealed months before his death that he'd been diagnosed with emphysema after smoking for decades. He died in ...

A recent ruling found the U.S. Food and Drug Administration went beyond what Congress specified in the Tobacco Control Act of ...

India has reported over 15 cases of HMPV. Meanwhile, China attributed the rise in cases to improved detection methods in ...

1 Division of Pulmonary and Critical Care, Department of Internal Medicine, Tannourine Governmental Hospital, Batroun, Lebanon. 2 Division of Pulmonary and Critical Care, Department of Internal ...

West Haven officials said they're instead considering building a new ... of drugs are used together. Given the high level of opioid poisonings that also involve benzodiazepines – in 2020 ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales ...